{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:39:53Z","timestamp":1793907593471,"version":"4.8.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2019-06467"],"award-info":[{"award-number":["RGPIN-2019-06467"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2021-02965"],"award-info":[{"award-number":["RGPIN-2021-02965"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Development of novel radiopharmaceuticals involves dosimetry calculations to validate safety and aid with selection of those that should be translated into the clinical environment. Dosimetry is critical for limiting radiation damage to organs at risk. The bone marrow is a limiting organ in radiopharmaceutical therapies (RPTs) for metastatic prostate cancer, for example, but there is room for improvement of bone marrow dosimetry in preclinical studies. Bone marrow <jats:italic>S<\/jats:italic>-values for Lutetium-177 (<jats:sup>177<\/jats:sup>Lu) in rodents have been published but they have not included tumor xenografts inoculated in the shoulder, which is how radiopharmaceuticals are often tested. Here, we aim at performing Monte Carlo simulations on digital mice phantoms including tumor xenografts, and to determine new bone marrow S-values that can potentially improve our understanding of the effect of RPTs in blood cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>\n              <jats:italic>S<\/jats:italic>-values for <jats:sup>177<\/jats:sup>Lu were simulated in the 4D Mouse Whole Body (MOBY) phantom, a hybrid voxel-based mouse model, using GATE v9.3 MC toolkit. Two phantoms of different resolutions and equal mass were created. 3D dose distributions were simulated and the corresponding organ to organ <jats:italic>S<\/jats:italic>-values were calculated. The resulting <jats:italic>S<\/jats:italic>-values were validated against reference values from OLINDA v2.2.3. Later, tumours of varying sizes were placed in the left shoulder and tumour-to-organ <jats:italic>S<\/jats:italic>-values were calculated from MC simulations with a <jats:sup>177<\/jats:sup>Lu source placed uniformly in these tumours.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The phantoms simulated here differed from the OLINDA phantom in both organ mass and geometry for many tissues; <jats:italic>S<\/jats:italic>-value deviations from OLINDA were correlated with these differences, as reported in previous studies, and ranged from 2% for the kidney self-dose in the higher resolution (HR) phantom to 477% for <jats:italic>S<\/jats:italic>(skeleton\u2190spleen) in the lower resolution (LR) phantom. <jats:italic>S<\/jats:italic>-values were simulated for the bone marrow in both phantoms; cross-dose values were greatest from the skeleton, brain, and lungs, while cross-doses from the simulated tumours were approximately constant at 3\u2009\u00d7\u200910<jats:sup>\u201315<\/jats:sup>\u00a0Gy\u00a0Bq<jats:sup>\u22121<\/jats:sup>\u00a0s<jats:sup>\u22121<\/jats:sup> across all tumour sizes. The components of the skeleton receiving the greatest tumour cross-doses from the tumours were the spine, skull and marrow. <jats:italic>S<\/jats:italic>-values targeting the bone marrow were compared to similar values from a previous study, whose phantom differed in tissue composition\u2014discrepancies ranged from 6% for S(BM\u2190kidneys) at LR to 87% for <jats:italic>S<\/jats:italic>(BM\u2190BM) at HR. In general, relative uncertainty in dose and dose factor deposited from one tissue to another was inversely proportional to the corresponding <jats:italic>S<\/jats:italic>-value magnitude, and lower uncertainties were yielded from simulations in the LR, large-voxel phantom.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Using the MOBY digital mouse phantom, we simulated bone marrow <jats:italic>S<\/jats:italic>-values for <jats:sup>177<\/jats:sup>Lu. We hope these values help researchers perform preclinical dosimetry in rodents including bone marrow and tumor xenografts and facilitate the translation of novel radiopharmaceuticals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40658-025-00752-5","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T03:05:18Z","timestamp":1751943918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["S-values for bone marrow dosimetry in preclinical radiopharmaceutical studies with rodents"],"prefix":"10.1186","volume":"12","author":[{"given":"Mohammed","family":"Obaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Segars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brosch-Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3766-620X","authenticated-orcid":false,"given":"Carlos","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"2","key":"752_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/HP.0000000000001000","volume":"116","author":"G Sgouros","year":"2019","unstructured":"Sgouros G. Radiopharmaceutical therapy. Health Phys. 2019;116(2):175\u20138.","journal-title":"Health Phys"},{"issue":"7","key":"752_CR2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006\u201313.","journal-title":"J Nucl Med"},{"issue":"6","key":"752_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D\u2019Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(6):920\u20136.","journal-title":"Eur Urol"},{"issue":"1","key":"752_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmrs.227","volume":"64","author":"L Emmett","year":"2017","unstructured":"Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52\u201360.","journal-title":"J Med Radiat Sci"},{"issue":"3","key":"752_CR5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"752_CR6","first-page":"62S","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med Off Publ Soc Nucl Med. 2005;46(Suppl 1):62S-S66.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"2","key":"752_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","volume":"52","author":"P Jackson","year":"2022","unstructured":"Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi KA. Radiation dosimetry in 177Lu-PSMA-617 therapy. Semin Nucl Med. 2022;52(2):243\u201354.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"752_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1874471008666150313114644","volume":"9","author":"T Das","year":"2015","unstructured":"Das T, Banerjee S. Theranostic applications of lutetium-177 in radionuclide therapy. Curr Radiopharm. 2015;9(1):94\u2013101.","journal-title":"Curr Radiopharm"},{"issue":"9","key":"752_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589\u2013608.","journal-title":"Nat Rev Drug Discov"},{"issue":"supplement 1","key":"752_CR10","first-page":"531","volume":"59","author":"M Hofman","year":"2018","unstructured":"Hofman M, Violet J, Sandhu S, Ferdinandus J, Thang SP, Iravani A, et al. High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial. J Nucl Med. 2018;59(supplement 1):531.","journal-title":"J Nucl Med"},{"issue":"10","key":"752_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/jlcr.3712","volume":"62","author":"P Kolenc Peitl","year":"2019","unstructured":"Kolenc Peitl P, Rangger C, Garnuszek P, Mikolajczak R, Hubalewska-Dydejczyk A, Maina T, et al. Clinical translation of theranostic radiopharmaceuticals: current regulatory status and recent examples. J Label Compd Radiopharm. 2019;62(10):673\u201383.","journal-title":"J Label Compd Radiopharm"},{"issue":"1","key":"752_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11307-023-01868-9","volume":"26","author":"LM Carter","year":"2024","unstructured":"Carter LM, Zanzonico PB. MIB guides: preclinical radiopharmaceutical dosimetry. Mol Imaging Biol. 2024;26(1):17\u201328.","journal-title":"Mol Imaging Biol"},{"key":"752_CR13","doi-asserted-by":"crossref","unstructured":"Stabin M, Flux G. Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine. Biomed Imaging Interv J [Internet]. 2007;3(2). Available from: http:\/\/www.biij.org\/2007\/2\/e28","DOI":"10.2349\/biij.3.2.e28"},{"issue":"2","key":"752_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2967\/jnmt.123.265668","volume":"52","author":"P Zanzonico","year":"2024","unstructured":"Zanzonico P. The MIRD schema for radiopharmaceutical dosimetry: a review. J Nucl Med Technol. 2024;52(2):74\u201385.","journal-title":"J Nucl Med Technol"},{"key":"752_CR15","unstructured":"Snyder WS. \u201cS,\u201d absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: Society of Nuclear Medicine; 1975. (NM\/MIRD pamphlet\u202f; no. 11)."},{"issue":"3","key":"752_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384.","journal-title":"J Nucl Med"},{"issue":"3","key":"752_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.mibio.2004.03.002","volume":"6","author":"W Segars","year":"2004","unstructured":"Segars W. Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol. 2004;6(3):149\u201359.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"752_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2967\/jnumed.109.070532","volume":"51","author":"MA Keenan","year":"2010","unstructured":"Keenan MA, Stabin MG, Segars WP, Fernald MJ. RADAR realistic animal model series for dose assessment. J Nucl Med. 2010;51(3):471\u20136.","journal-title":"J Nucl Med"},{"issue":"6","key":"752_CR19","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med Off Publ Soc Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"1","key":"752_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2967\/jnumed.117.196261","volume":"59","author":"MG Stabin","year":"2018","unstructured":"Stabin MG, Siegel JA. RADAR dose estimate report: a compendium of radiopharmaceutical dose estimates based on OLINDA\/EXM version 2.0. J Nucl Med. 2018;59(1):154\u201360.","journal-title":"J Nucl Med"},{"issue":"1","key":"752_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1088\/0031-9155\/58\/1\/169","volume":"58","author":"T Xie","year":"2013","unstructured":"Xie T, Zaidi H. Monte Carlo-based evaluation of S-values in mouse models for positron-emitting radionuclides. Phys Med Biol. 2013;58(1):169\u201382.","journal-title":"Phys Med Biol"},{"issue":"6","key":"752_CR22","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1088\/0031-9155\/61\/6\/2333","volume":"61","author":"T Kostou","year":"2016","unstructured":"Kostou T, Papadimitroulas P, Loudos G, Kagadis GC. A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom. Phys Med Biol. 2016;61(6):2333\u201355.","journal-title":"Phys Med Biol"},{"issue":"3","key":"752_CR23","first-page":"438","volume":"22","author":"E Larsson","year":"2007","unstructured":"Larsson E, Strand SE, Ljungberg M, J\u00f6nsson BA. Mouse S-factors based on Monte Carlo simulations in the anatomical realistic moby phantom for internal dosimetry. Cancer Biother Radiopharm. 2007;22(3):438\u201342.","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"752_CR24","doi-asserted-by":"publisher","first-page":"052501","DOI":"10.1118\/1.4800801","volume":"40","author":"T Mauxion","year":"2013","unstructured":"Mauxion T, Barbet J, Suhard J, Pouget JP, Poirot M, Bardi\u00e8s M. Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data: dosimetry based on improved realism of hybrid mouse models. Med Phys. 2013;40(5):052501.","journal-title":"Med Phys"},{"issue":"2","key":"752_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1148\/radiology.139.2.6939019","volume":"139","author":"RR Weichselbaum","year":"1981","unstructured":"Weichselbaum RR, Greenberger JS, Schmidt A, Karpas A, Moloney WC, Little JB. In vitro radiosensitivity of human leukemia cell lines. Radiology. 1981;139(2):485\u20137.","journal-title":"Radiology"},{"issue":"6","key":"752_CR26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"752_CR27","first-page":"405","volume":"17","author":"TM Fliedner","year":"2002","unstructured":"Fliedner TM, Graessle D, Paulsen C, Reimers K. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm. 2002;17(4):405\u201326.","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"752_CR28","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"752_CR29","first-page":"97","volume":"43","author":"WE Bolch","year":"2002","unstructured":"Bolch WE, Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. J Nucl Med Off Publ Soc Nucl Med. 2002;43(1):97\u2013108.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"9","key":"752_CR30","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2967\/jnumed.111.087957","volume":"52","author":"JC Pichardo","year":"2011","unstructured":"Pichardo JC, Milner RJ, Bolch WE. MRI measurement of bone marrow cellularity for radiation dosimetry. J Nucl Med. 2011;52(9):1482\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"752_CR31","first-page":"427","volume":"17","author":"MG Stabin","year":"2002","unstructured":"Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm. 2002;17(4):427\u201333.","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"752_CR32","first-page":"689","volume":"34","author":"G Sgouros","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med Off Publ Soc Nucl Med. 1993;34(4):689\u201394.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"752_CR33","unstructured":"Spiers FW. Beta particle dosimetry in trabecular bone. Pp 95\u2013108 Delayed Eff Bone-Seek Radionucl Mays Charles W Ed Salt Lake City Univ Utah Press 1969 [Internet]. 1969 Oct 31. Available from: https:\/\/www.osti.gov\/biblio\/4746249"},{"key":"752_CR34","doi-asserted-by":"crossref","unstructured":"Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources: 1, methods [Internet]. United States. 1987. Available from: https:\/\/www.osti.gov\/biblio\/6233735","DOI":"10.2172\/6233735"},{"issue":"1","key":"752_CR35","first-page":"189","volume":"41","author":"LG Bouchet","year":"2000","unstructured":"Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med Off Publ Soc Nucl Med. 2000;41(1):189\u2013212.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"1","key":"752_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40658-022-00495-7","volume":"9","author":"J Hemmingsson","year":"2022","unstructured":"Hemmingsson J, Svensson J, Van Der Meulen NP, M\u00fcller C, Bernhardt P. Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90. EJNMMI Phys. 2022;9(1):65.","journal-title":"EJNMMI Phys"},{"issue":"S3","key":"752_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/1097-0142(19940201)73:3+<951::AID-CNCR2820731330>3.0.CO;2-1","volume":"73","author":"T Edmond Hui","year":"1994","unstructured":"Edmond Hui T, Fisher DR, Kuhn JA, Williams LE, Nourigat C, Badger CC, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer. 1994;73(S3):951\u20137.","journal-title":"Cancer"},{"issue":"7","key":"752_CR38","first-page":"1243","volume":"39","author":"MS Muthuswamy","year":"1998","unstructured":"Muthuswamy MS, Roberson PL, Buchsbaum DJ. A mouse bone marrow dosimetry model. J Nucl Med Off Publ Soc Nucl Med. 1998;39(7):1243\u20137.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"4","key":"752_CR39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1088\/0031-9155\/52\/4\/010","volume":"52","author":"A Bitar","year":"2007","unstructured":"Bitar A, Lisbona A, Thedrez P, Maurel CS, Forestier DL, Barbet J, et al. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP). Phys Med Biol. 2007;52(4):1013\u201325.","journal-title":"Phys Med Biol"},{"issue":"4","key":"752_CR40","first-page":"343","volume":"51","author":"A Bitar","year":"2007","unstructured":"Bitar A, Lisbona A, Bardi\u00e8s M. S-factor calculations for mouse models using Monte-Carlo simulations. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of. 2007;51(4):343\u201351.","journal-title":"Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of"},{"key":"752_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejmp.2022.02.021","volume":"96","author":"G Tamborino","year":"2022","unstructured":"Tamborino G, Nonnekens J, Struelens L, De Saint-Hubert M, Verburg FA, Konijnenberg MW. Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: influence of radionuclide choice. Phys Med. 2022;96:90\u2013100.","journal-title":"Phys Med"},{"issue":"1","key":"752_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2967\/jnumed.112.107524","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Garske-Rom\u00e1n U, Granberg D, Johansson S, Widstr\u00f6m C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing177 Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33\u201341.","journal-title":"J Nucl Med"},{"issue":"7","key":"752_CR43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"752_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000179221","volume":"17","author":"HA Lehr","year":"1997","unstructured":"Lehr HA, Skelly M, Buhler K, Anderson B, Delisser HM, Gown AM. Microvascular endothelium of human tumor xenografts expresses mouse (= Host) CD31. Int J Microcirc. 1997;17(3):138\u201342.","journal-title":"Int J Microcirc"},{"issue":"1","key":"752_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1479-5876-11-110","volume":"11","author":"BL Hylander","year":"2013","unstructured":"Hylander BL, Punt N, Tang H, Hillman J, Vaughan M, Bshara W, et al. Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med. 2013;11(1):110.","journal-title":"J Transl Med"},{"issue":"2","key":"752_CR46","first-page":"268","volume":"22","author":"H Uusij\u00e4rvi","year":"2007","unstructured":"Uusij\u00e4rvi H, Bernhardt P, Forssell-Aronsson E. Translation of dosimetric results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation. Cancer Biother Radiopharm. 2007;22(2):268\u201374.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"752_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1667\/0033-7587(2001)156[0028:AMMFCT]2.0.CO;2","volume":"156","author":"AA Flynn","year":"2001","unstructured":"Flynn AA, Green AJ, Pedley RB, Boxer GM, Boden R, Begent RHJ. A mouse model for calculating the absorbed beta-particle dose from131 I- and90 Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor. Radiat Res. 2001;156(1):28\u201335.","journal-title":"Radiat Res"},{"key":"752_CR48","doi-asserted-by":"crossref","unstructured":"Segars WP, Tsui BM. The MCAT, NCAT, XCAT, and MOBY computational human and mouse phantoms. Handb Anat Models Radiat Dosim Taylor Francis Lond 2009. 2009;105\u201333","DOI":"10.1201\/EBK1420059793-c5"},{"issue":"3\u20134","key":"752_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89: approved by the commission in September 2001. Ann ICRP. 2002;32(3\u20134):1\u2013277.","journal-title":"Ann ICRP"},{"issue":"9","key":"752_CR50","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med Off Publ Soc Nucl Med. 2006;47(9):1467\u201375.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"708","key":"752_CR51","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1259\/0007-1285-59-708-1209","volume":"59","author":"HQ Woodard","year":"1986","unstructured":"Woodard HQ, White DR. The composition of body tissues. Br J Radiol. 1986;59(708):1209\u201318.","journal-title":"Br J Radiol"},{"issue":"19","key":"752_CR52","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1088\/0031-9155\/49\/19\/007","volume":"49","author":"S Jan","year":"2004","unstructured":"Jan S, Santin G, Strul D, Staelens S, Assi\u00e9 K, Autret D, et al. GATE: a simulation toolkit for PET and SPECT. Phys Med Biol. 2004;49(19):4543\u201361.","journal-title":"Phys Med Biol"},{"issue":"4","key":"752_CR53","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1088\/0031-9155\/56\/4\/001","volume":"56","author":"S Jan","year":"2011","unstructured":"Jan S, Benoit D, Becheva E, Carlier T, Cassol F, Descourt P, et al. GATE V6: a major enhancement of the GATE simulation platform enabling modelling of CT and radiotherapy. Phys Med Biol. 2011;56(4):881\u2013901.","journal-title":"Phys Med Biol"},{"key":"752_CR54","doi-asserted-by":"publisher","first-page":"064301","DOI":"10.1118\/1.4871617","volume":"41","author":"D Sarrut","year":"2014","unstructured":"Sarrut D, Bardi\u00e8s M, Boussion N, Freud N, Jan S, L\u00e9tang JM, et al. A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications: GATE for dosimetry. Med Phys. 2014;41:064301.","journal-title":"Med Phys"},{"key":"752_CR55","first-page":"1011","volume":"57","author":"D Villoing","year":"2016","unstructured":"Villoing D, Garcia MP, Bardi\u00e8s M. Impact of the Monte Carlo code GATE for targeted radionuclide therapy (TRT): imaging and dosimetric calculations. J Nucl Med. 2016;57:1011\u20131011.","journal-title":"J Nucl Med"},{"issue":"1","key":"752_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1088\/0031-9155\/41\/1\/009","volume":"41","author":"U Schneider","year":"1996","unstructured":"Schneider U, Pedroni E, Lomax A. The calibration of CT Hounsfield units for radiotherapy treatment planning. Phys Med Biol. 1996;41(1):111\u201324.","journal-title":"Phys Med Biol"},{"key":"752_CR57","doi-asserted-by":"crossref","unstructured":"Baldwin S. Compute Canada: advancing computational research. In: Journal Physics Conference Series. 2012;341:012001.","DOI":"10.1088\/1742-6596\/341\/1\/012001"},{"issue":"12","key":"752_CR58","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1118\/1.1517611","volume":"29","author":"BRB Walters","year":"2002","unstructured":"Walters BRB, Kawrakow I, Rogers DWO. History by history statistical estimators in the BEAM code system. Med Phys. 2002;29(12):2745\u201352.","journal-title":"Med Phys"},{"issue":"4","key":"752_CR59","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.ijrobp.2006.03.039","volume":"65","author":"IJ Chetty","year":"2006","unstructured":"Chetty IJ, Rosu M, Kessler ML, Fraass BA, Ten Haken RK, Kong FM, et al. Reporting and analyzing statistical uncertainties in Monte Carlo\u2013based treatment planning. Int J Radiat Oncol. 2006;65(4):1249\u201359.","journal-title":"Int J Radiat Oncol"},{"key":"752_CR60","doi-asserted-by":"crossref","unstructured":"Boutaleb S, Pouget JP, Hindorf C, Pelegrin A, Barbet J, Kotzki PO et al. Impact of mouse model on preclinical dosimetry in targeted radionuclide therapy. In: Proceedings IEEE. 2009;97(12):2076\u201385.","DOI":"10.1109\/JPROC.2009.2026921"},{"issue":"11","key":"752_CR61","first-page":"1960","volume":"45","author":"C Hindorf","year":"2004","unstructured":"Hindorf C, Ljungberg M, Strand SE. Evaluation of parameters influencing S values in mouse dosimetry. J Nucl Med Off Publ Soc Nucl Med. 2004;45(11):1960\u20135.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"2","key":"752_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/japplphysiol.00615.2019","volume":"128","author":"C Bauer","year":"2020","unstructured":"Bauer C, Krueger M, Lamm WJE, Glenny RW, Beichel RR. lapdMouse: associating lung anatomy with local particle deposition in mice. J Appl Physiol. 2020;128(2):309\u201323.","journal-title":"J Appl Physiol"},{"issue":"6","key":"752_CR63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.media.2010.04.008","volume":"14","author":"M Baiker","year":"2010","unstructured":"Baiker M, Milles J, Dijkstra J, Henning TD, Weber AW, Que I, et al. Atlas-based whole-body segmentation of mice from low-contrast Micro-CT data. Med Image Anal. 2010;14(6):723\u201337.","journal-title":"Med Image Anal"},{"issue":"3","key":"752_CR64","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1088\/0031-9155\/52\/3\/003","volume":"52","author":"B Dogdas","year":"2007","unstructured":"Dogdas B, Stout D, Chatziioannou AF, Leahy RM. Digimouse: a 3D whole body mouse atlas from CT and cryosection data. Phys Med Biol. 2007;52(3):577\u201387.","journal-title":"Phys Med Biol"},{"issue":"2","key":"752_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13139-020-00640-z","volume":"54","author":"A Gupta","year":"2020","unstructured":"Gupta A, Lee MS, Kim JH, Lee DS, Lee JS. Preclinical voxel-based dosimetry in theranostics: a Review. Nucl Med Mol Imaging. 2020;54(2):86\u201397.","journal-title":"Nucl Med Mol Imaging"},{"issue":"11","key":"752_CR66","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1118\/1.1315313","volume":"27","author":"DA Rajon","year":"2000","unstructured":"Rajon DA, Jokisch DW, Patton PW, Shah AP, Bolch WE. Voxel size effects in three-dimensional nuclear magnetic resonance microscopy performed for trabecular bone dosimetry. Med Phys. 2000;27(11):2624\u201335.","journal-title":"Med Phys"},{"issue":"8","key":"752_CR67","doi-asserted-by":"publisher","first-page":"082502","DOI":"10.1118\/1.4812684","volume":"40","author":"M Fern\u00e1ndez","year":"2013","unstructured":"Fern\u00e1ndez M, H\u00e4nscheid H, Mauxion T, Bardi\u00e8s M, Kletting P, Glatting G, et al. A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculation: fast rescaling of voxel S values. Med Phys. 2013;40(8):082502.","journal-title":"Med Phys"},{"issue":"2","key":"752_CR68","first-page":"344","volume":"46","author":"AP Shah","year":"2005","unstructured":"Shah AP, Bolch WE, Rajon DA, Patton PW, Jokisch DW. A paired-image radiation transport model for skeletal dosimetry. J Nucl Med Off Publ Soc Nucl Med. 2005;46(2):344\u201353.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"5","key":"752_CR69","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1118\/1.1898463","volume":"32","author":"AP Shah","year":"2005","unstructured":"Shah AP, Rajon DA, Patton PW, Jokisch DW, Bolch WE. Accounting for beta-particle energy loss to cortical bone via paired-image radiation transport (PIRT). Med Phys. 2005;32(5):1354\u201366.","journal-title":"Med Phys"},{"issue":"14","key":"752_CR70","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1088\/0031-9155\/58\/14\/4717","volume":"58","author":"SJ Wilderman","year":"2013","unstructured":"Wilderman SJ, Roberson PL, Bolch WE, Dewaraja YK. Investigation of effect of variations in bone fraction and red marrow cellularity on bone marrow dosimetry in radio-immunotherapy. Phys Med Biol. 2013;58(14):4717\u201331.","journal-title":"Phys Med Biol"},{"issue":"3","key":"752_CR71","doi-asserted-by":"publisher","first-page":"035016","DOI":"10.1088\/1361-6560\/abd3ef","volume":"66","author":"J Tranel","year":"2021","unstructured":"Tranel J, Feng FY, James SS, Hope TA. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Phys Med Biol. 2021;66(3):035016.","journal-title":"Phys Med Biol"},{"issue":"12","key":"752_CR72","doi-asserted-by":"publisher","first-page":"125008","DOI":"10.1088\/1361-6560\/ad4f49","volume":"69","author":"A Bertinetti","year":"2024","unstructured":"Bertinetti A, Palmer B, Bradshaw T, Culberson W. Investigation of a measurement-based dosimetry approach to beta particle-emitting radiopharmaceutical therapy nuclides across tissue interfaces. Phys Med Biol. 2024;69(12):125008.","journal-title":"Phys Med Biol"},{"issue":"S3","key":"752_CR73","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/1097-0142(19940201)73:3+<958::AID-CNCR2820731331>3.0.CO;2-E","volume":"73","author":"BG Beatty","year":"1994","unstructured":"Beatty BG, Kuhn JA, Edmond Hui T, Fisher DR, Williams LE, David BJ. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a90y-labeled immunoconjugate. Cancer. 1994;73(S3):958\u201365.","journal-title":"Cancer"},{"issue":"2","key":"752_CR74","first-page":"252","volume":"44","author":"G Henriksen","year":"2003","unstructured":"Henriksen G, Fisher DR, Roeske JC, Bruland \u00d8S, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med Off Publ Soc Nucl Med. 2003;44(2):252\u20139.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"1","key":"752_CR75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40658-014-0104-x","volume":"2","author":"W Woliner-van Der Weg","year":"2015","unstructured":"Woliner-van Der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey RM, et al. Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Phys. 2015;2(1):5.","journal-title":"EJNMMI Phys"},{"issue":"9","key":"752_CR76","doi-asserted-by":"publisher","first-page":"095007","DOI":"10.1088\/1361-6560\/ab134b","volume":"64","author":"A Gupta","year":"2019","unstructured":"Gupta A, Lee MS, Kim JH, Park S, Park HS, Kim SE, et al. Preclinical voxel-based dosimetry through GATE Monte Carlo simulation using PET\/CT imaging of mice. Phys Med Biol. 2019;64(9):095007.","journal-title":"Phys Med Biol"},{"key":"752_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.apradiso.2019.01.019","volume":"146","author":"LI L\u00f3pez-Coello","year":"2019","unstructured":"L\u00f3pez-Coello LI, Torres-Garc\u00eda E, D\u00edaz-S\u00e1nchez LE, Oros-Pantoja R, Aranda-Lara L. Differences in the S value between male and female murine model for diagnostic, therapeutic and theragnostic radionuclides. Appl Radiat Isot. 2019;146:61\u20135.","journal-title":"Appl Radiat Isot"},{"issue":"10","key":"752_CR78","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1088\/0031-9155\/57\/10\/3207","volume":"57","author":"RF Hobbs","year":"2012","unstructured":"Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for223 Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol. 2012;57(10):3207\u201322.","journal-title":"Phys Med Biol"},{"issue":"4","key":"752_CR79","doi-asserted-by":"publisher","first-page":"045010","DOI":"10.1088\/1361-6560\/ab6b42","volume":"65","author":"GM Pinto","year":"2020","unstructured":"Pinto GM, Bonifacio DAB, De S\u00e1 LV, Lima LFC, Vieira IF, Lopes RT. A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations. Phys Med Biol. 2020;65(4):045010.","journal-title":"Phys Med Biol"},{"issue":"9","key":"752_CR80","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1088\/0031-9155\/59\/9\/2183","volume":"59","author":"Y Perrot","year":"2014","unstructured":"Perrot Y, Degoul F, Auzeloux P, Bonnet M, Cachin F, Chezal JM, et al. Internal dosimetry through GATE simulations of preclinical radiotherapy using a melanin-targeting ligand. Phys Med Biol. 2014;59(9):2183\u201398.","journal-title":"Phys Med Biol"}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-025-00752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40658-025-00752-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-025-00752-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T15:04:08Z","timestamp":1751987048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmiphys.springeropen.com\/articles\/10.1186\/s40658-025-00752-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1186\/s40658-025-00752-5","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}